FR2942797B1 - Derives de benzothiazines, leur preparation et leur application a titre de medicaments - Google Patents

Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Info

Publication number
FR2942797B1
FR2942797B1 FR0951336A FR0951336A FR2942797B1 FR 2942797 B1 FR2942797 B1 FR 2942797B1 FR 0951336 A FR0951336 A FR 0951336A FR 0951336 A FR0951336 A FR 0951336A FR 2942797 B1 FR2942797 B1 FR 2942797B1
Authority
FR
France
Prior art keywords
medicaments
preparation
application
benzothiazine derivatives
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0951336A
Other languages
English (en)
Other versions
FR2942797A1 (fr
Inventor
Michel Perez
Marie Lamothe
Didier Junquero
Yves Rival
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0951336A priority Critical patent/FR2942797B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to KR1020117022812A priority patent/KR101701531B1/ko
Priority to SG2011063146A priority patent/SG174208A1/en
Priority to ES10706624.3T priority patent/ES2483516T3/es
Priority to AU2010220335A priority patent/AU2010220335B2/en
Priority to RU2011139014/04A priority patent/RU2523791C2/ru
Priority to UAA201111590A priority patent/UA105040C2/uk
Priority to GEAP201012398A priority patent/GEP20135832B/en
Priority to ARP100100618A priority patent/AR075777A1/es
Priority to EP10706624.3A priority patent/EP2403840B1/fr
Priority to CA2753630A priority patent/CA2753630C/fr
Priority to SA110310181A priority patent/SA110310181B1/ar
Priority to NZ595276A priority patent/NZ595276A/xx
Priority to PCT/EP2010/052609 priority patent/WO2010100139A1/fr
Priority to PL10706624T priority patent/PL2403840T3/pl
Priority to MA34191A priority patent/MA33138B1/fr
Priority to BRPI1010243A priority patent/BRPI1010243A2/pt
Priority to MYPI2011004096A priority patent/MY160819A/en
Priority to MX2011008942A priority patent/MX2011008942A/es
Priority to JP2011552415A priority patent/JP5650139B2/ja
Priority to US13/254,473 priority patent/US9187438B2/en
Priority to CN201080010207.7A priority patent/CN102341379B/zh
Priority to TW099106123A priority patent/TWI495636B/zh
Publication of FR2942797A1 publication Critical patent/FR2942797A1/fr
Application granted granted Critical
Publication of FR2942797B1 publication Critical patent/FR2942797B1/fr
Priority to TN2011000429A priority patent/TN2011000429A1/fr
Priority to IL214907A priority patent/IL214907A/en
Priority to CL2011002171A priority patent/CL2011002171A1/es
Priority to CO11128125A priority patent/CO6501175A2/es
Priority to ZA2011/07104A priority patent/ZA201107104B/en
Priority to HK12106611.2A priority patent/HK1165802A1/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines

Abstract

La présente invention a pour objet des dérivés de benzothiazine ayant la capacité d'inhiber la 11β-HSD1 non seulement au niveau enzymatique mais également au niveau cellulaire. Les composés de la présente invention sont de formule générale (I) : Dans laquelle notamment : R représente l'hydrogène ; R représente un naphtyle ou un 1,2,3,4-tetrahydro-naphtalène ; R représente un méthyle ou éthyle R et R' représentent l'hydrogène.
FR0951336A 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments Expired - Fee Related FR2942797B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
FR0951336A FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments
MX2011008942A MX2011008942A (es) 2009-03-03 2010-03-02 Derivados de benzotiazinas, su preparacion y aplicacion como farmacos.
ES10706624.3T ES2483516T3 (es) 2009-03-03 2010-03-02 Derivados de benzotiazinas, su preparación y aplicación como fármacos
MYPI2011004096A MY160819A (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
RU2011139014/04A RU2523791C2 (ru) 2009-03-03 2010-03-02 Производные бензотиазинов, их получение и применение в качестве лекарств
UAA201111590A UA105040C2 (uk) 2009-03-03 2010-03-02 Похідні бензотіазинів, їх одержання та застосування як ліків
GEAP201012398A GEP20135832B (en) 2009-03-03 2010-03-02 Benzothiazines derivatives, preparation thereof, and their application as drugs
SG2011063146A SG174208A1 (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
EP10706624.3A EP2403840B1 (fr) 2009-03-03 2010-03-02 Dérivés des benzothiazines, leur préparation et leur application en tant que médicaments
CA2753630A CA2753630C (fr) 2009-03-03 2010-03-02 Derives des benzothiazines, leur preparation et leur application en tant que medicaments
SA110310181A SA110310181B1 (ar) 2009-03-03 2010-03-02 مشتقات بنزوثيازين ومستحضرات منها واستخدامها كعقاقير
NZ595276A NZ595276A (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
PCT/EP2010/052609 WO2010100139A1 (fr) 2009-03-03 2010-03-02 Dérivés des benzothiazines, leur préparation et leur application en tant que médicaments
JP2011552415A JP5650139B2 (ja) 2009-03-03 2010-03-02 ベンゾチアジン誘導体、それらの製造および薬剤としてのそれらの応用
KR1020117022812A KR101701531B1 (ko) 2009-03-03 2010-03-02 벤조티아진 유도체, 이의 제조방법 및 약물로서의 용도
BRPI1010243A BRPI1010243A2 (pt) 2009-03-03 2010-03-02 derivados de benzotiazinas, preparação dos mesmos e aplicação dos mesmos como fármacos
AU2010220335A AU2010220335B2 (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
ARP100100618A AR075777A1 (es) 2009-03-03 2010-03-02 Derivados de benzotiazina, su preparacion y aplicacion como farmacos para la inhibicion de 11beta-hidroxiesteroide deshidrogenasa tipo i (11betahsd1)
PL10706624T PL2403840T3 (pl) 2009-03-03 2010-03-02 Pochodne benzotiazyn, ich wytwarzanie i ich zastosowanie jako leków
US13/254,473 US9187438B2 (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
CN201080010207.7A CN102341379B (zh) 2009-03-03 2010-03-02 苯并噻嗪衍生物、其制备方法及其作为药物的应用
MA34191A MA33138B1 (fr) 2009-03-03 2010-03-02 Derives de benzothiazines, leur preparation et leur application a titre de medicaments
TW099106123A TWI495636B (zh) 2009-03-03 2010-03-03 苯并硫氮衍生物、其製備及作為藥物之應用
TN2011000429A TN2011000429A1 (en) 2009-03-03 2011-08-19 Derivatives of benzothiazines, preparation thereof and application thereof as drugs
IL214907A IL214907A (en) 2009-03-03 2011-08-31 Derivatives of benzothiazines, methods for their preparation and medicinal compounds containing them
CL2011002171A CL2011002171A1 (es) 2009-03-03 2011-09-02 Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer.
CO11128125A CO6501175A2 (es) 2009-03-03 2011-09-29 Derivados de benzotiazinas, su preparación y aplicación como fármacos
ZA2011/07104A ZA201107104B (en) 2009-03-03 2011-09-29 Derivatives of benzothiazines,preparation thereof and application thereof as drugs
HK12106611.2A HK1165802A1 (en) 2009-03-03 2012-07-06 Derivatives of benzothiazines, preparation thereof and application thereof as drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0951336A FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Publications (2)

Publication Number Publication Date
FR2942797A1 FR2942797A1 (fr) 2010-09-10
FR2942797B1 true FR2942797B1 (fr) 2011-04-29

Family

ID=40790339

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0951336A Expired - Fee Related FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Country Status (29)

Country Link
US (1) US9187438B2 (fr)
EP (1) EP2403840B1 (fr)
JP (1) JP5650139B2 (fr)
KR (1) KR101701531B1 (fr)
CN (1) CN102341379B (fr)
AR (1) AR075777A1 (fr)
AU (1) AU2010220335B2 (fr)
BR (1) BRPI1010243A2 (fr)
CA (1) CA2753630C (fr)
CL (1) CL2011002171A1 (fr)
CO (1) CO6501175A2 (fr)
ES (1) ES2483516T3 (fr)
FR (1) FR2942797B1 (fr)
GE (1) GEP20135832B (fr)
HK (1) HK1165802A1 (fr)
IL (1) IL214907A (fr)
MA (1) MA33138B1 (fr)
MX (1) MX2011008942A (fr)
MY (1) MY160819A (fr)
NZ (1) NZ595276A (fr)
PL (1) PL2403840T3 (fr)
RU (1) RU2523791C2 (fr)
SA (1) SA110310181B1 (fr)
SG (1) SG174208A1 (fr)
TN (1) TN2011000429A1 (fr)
TW (1) TWI495636B (fr)
UA (1) UA105040C2 (fr)
WO (1) WO2010100139A1 (fr)
ZA (1) ZA201107104B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
CN103271923B (zh) * 2013-06-28 2014-11-26 安徽中医学院 一种苯并噻嗪衍生物的医药用途
CN103275035B (zh) * 2013-06-28 2014-11-26 安徽中医学院 苯并噻嗪类化合物、其制备方法及其抗肿瘤用途
CN103304513B (zh) * 2013-06-28 2015-02-04 安徽中医学院 一类1,2-苯并噻嗪类化合物、制备方法及其应用
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CN106243046B (zh) * 2016-08-02 2019-07-05 南京工业大学 一种甲基二磺隆的制备方法
EP3606921B1 (fr) 2017-04-06 2022-06-01 Inventiva Nouveaux composés inhibiteurs de l'interaction yap/taz-tead et leur utilisation dans le traitement du mésothéliome malin
EP3632908A1 (fr) 2018-10-02 2020-04-08 Inventiva Inhibiteurs de l'interaction yap / taz-tead et leur utilisation dans le traitement du cancer
WO2023154412A1 (fr) * 2022-02-12 2023-08-17 Miralogx Llc Composés anti-inflammatoires, compositions pharmaceutiques et méthodes de traitement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
US3808205A (en) * 1971-09-10 1974-04-30 Warner Lambert Co Process for the preparation of 4-hydroxy-3-carbamyl-2h-1,2-benzothiazine 1,1-dioxides and 4-hydroxy-3(2h)-1,2-benzothiazine carboxylate-1,1-dioxides
US4289879A (en) * 1980-09-29 1981-09-15 Pfizer Inc. Synthetic method and intermediate for piroxicam
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
WO2002030914A1 (fr) * 2000-10-12 2002-04-18 Dr. Reddy's Research Foundation Sels de derives de benzothiazine et de benzoxazine et compositions pharmaceutiques a base de ces sels
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
ATE455547T1 (de) * 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
CA2625871C (fr) * 2005-10-20 2014-07-08 Merck & Co., Inc. Derives de triazol en tant qu'inhibiteurs de 11-beta-hydroxysteroide deshydrogenase-1
TWI399367B (zh) * 2005-11-21 2013-06-21 Shionogi & Co 具有Ｉ型１１β羥基類固醇脫氫酶抑制活性之雜環化合物
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体

Also Published As

Publication number Publication date
CA2753630A1 (fr) 2010-09-10
KR101701531B1 (ko) 2017-02-01
RU2011139014A (ru) 2013-04-10
HK1165802A1 (en) 2012-10-12
CN102341379A (zh) 2012-02-01
EP2403840A1 (fr) 2012-01-11
JP2012519203A (ja) 2012-08-23
JP5650139B2 (ja) 2015-01-07
BRPI1010243A2 (pt) 2016-03-22
PL2403840T3 (pl) 2014-10-31
TN2011000429A1 (en) 2013-03-27
IL214907A (en) 2015-02-26
WO2010100139A1 (fr) 2010-09-10
US20110319326A1 (en) 2011-12-29
TWI495636B (zh) 2015-08-11
MA33138B1 (fr) 2012-03-01
US9187438B2 (en) 2015-11-17
EP2403840B1 (fr) 2014-05-14
SG174208A1 (en) 2011-10-28
ZA201107104B (en) 2012-05-30
ES2483516T3 (es) 2014-08-06
UA105040C2 (uk) 2014-04-10
CO6501175A2 (es) 2012-08-15
RU2523791C2 (ru) 2014-07-27
AU2010220335A1 (en) 2011-10-13
AU2010220335B2 (en) 2014-05-29
CA2753630C (fr) 2017-05-30
KR20110122758A (ko) 2011-11-10
CL2011002171A1 (es) 2012-04-13
MY160819A (en) 2017-03-31
FR2942797A1 (fr) 2010-09-10
IL214907A0 (en) 2011-11-30
TW201035064A (en) 2010-10-01
NZ595276A (en) 2013-06-28
GEP20135832B (en) 2013-05-27
MX2011008942A (es) 2011-09-27
AR075777A1 (es) 2011-04-27
SA110310181B1 (ar) 2013-08-27
CN102341379B (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
FR2942797B1 (fr) Derives de benzothiazines, leur preparation et leur application a titre de medicaments
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30765B1 (fr) Derives innovants du thiophene
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MA31953B1 (fr) Nouveaux derives du thiophene.
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MY151295A (en) Pyrimidyl indoline compound
MA33528B1 (fr) Derives pyridin-4-yliques
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
WO2007062338A3 (fr) Formulations solides
TN2010000173A1 (fr) Antagonistes de cgrp
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20211105